Discontinued — last reported Q4 '24
Tyvyt — Revenue
Eli Lilly Tyvyt — Revenue decreased by 9.4% to $136.10M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 19.7%, from $113.70M to $136.10M. Over 3 years (FY 2021 to FY 2024), Tyvyt — Revenue shows an upward trend with a 8.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market share or successful clinical adoption of the therapy, while a decrease may signal increased competition, patent expiration, or shifts in oncology treatment standards.
Detailed definition
This metric represents the total gross sales generated from the Tyvyt product line, a key oncology therapeutic within th...
Peer comparison
Comparable to oncology-specific product revenue lines reported by other major pharmaceutical companies, often evaluated against broader therapeutic area growth benchmarks.
lly_segment_tyvyt_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $105.00M | $125.60M | $77.80M | $85.50M | $73.60M | $76.80M | $57.40M | $61.00M | $103.60M | $115.10M | $113.70M | $116.70M | $123.00M | $150.20M | $136.10M |
| QoQ Change | — | +19.6% | -38.1% | +9.9% | -13.9% | +4.3% | -25.3% | +6.3% | +69.8% | +11.1% | -1.2% | +2.6% | +5.4% | +22.1% | -9.4% |
| YoY Change | — | — | — | — | -29.9% | -38.9% | -26.2% | -28.7% | +40.8% | +49.9% | +98.1% | +91.3% | +18.7% | +30.5% | +19.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's tyvyt — revenue?
- Eli Lilly (LLY) reported tyvyt — revenue of $136.10M in Q4 2024.
- How has Eli Lilly's tyvyt — revenue changed year-over-year?
- Eli Lilly's tyvyt — revenue increased by 19.7% year-over-year, from $113.70M to $136.10M.
- What is the long-term trend for Eli Lilly's tyvyt — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's tyvyt — revenue has grown at a 8.0% compound annual growth rate (CAGR), from $418.10M to $526.00M.
- What does tyvyt — revenue mean?
- The total revenue generated from sales of the Tyvyt oncology drug.